Breakthrough T1D Request for Applications: Advancing Technologies to Enhance Engraftment in Cell Therapy for T1D
Funds research to improve engraftment and function of insulin-producing cells at non-liver sites for type 1 diabetes therapy, focusing on overcoming barriers like inflammation and poor vascularization.
Funder: Breakthrough T1D
Due Dates: January 10, 2025 (Letter of Intent) | February 21, 2025 (Full proposal)
Funding Amounts: Up to $300,000 per year for up to 2 years; larger awards may be considered with discussion.
Summary: Supports research to advance technologies improving engraftment and function of insulin-producing cells for type 1 diabetes therapy at alternative transplantation sites.
Description
This opportunity from Breakthrough T1D funds preclinical and clinical research projects aimed at accelerating the development of innovative technologies and strategies to enhance the survival, engraftment, and function of insulin-producing cells following transplantation at extrahepatic (non-liver) sites for type 1 diabetes (T1D) cell therapy. The initiative addresses key barriers such as inflammation, hypoxia, and poor vascularization at alternative implantation sites, which currently limit cell survival and function. Research should focus on direct interventions targeting the beta cell graft or on modifying/monitoring the graft microenvironment, with an emphasis on advancing technologies into late preclinical or early clinical development.
